ITUB:NYSEItau Unibanco Banco Holding SA Analysis
Data as of 2026-05-25 - not real-time
$7.82
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
ITUB trades at a forward PE of about 7.9, well below the industry average of 16.8, indicating a clear undervaluation. The stock offers a dividend yield of 1.35% with a payout ratio near 75%, supported by a massive cash pile exceeding $530 bn. Recent earnings showed a 10% YoY increase in net income despite a 2% dip in revenue, suggesting resilient profitability. The price‑to‑book ratio of 2.07 and price‑to‑sales of 0.62 further underscore the value tilt. Technicals reveal a neutral trend, with the 20‑day SMA (8.25) just above the current price (7.82) and the RSI at 39, hinting at modest upside potential. The MACD remains bearish, and the stock is hovering just above a support level of 7.64, while resistance sits near 8.94. Volatility is elevated at roughly 31% over the past month, and a beta above 1.3 signals higher sensitivity to market moves. The broader macro environment adds geographic and regulatory risk, given Brazil’s evolving banking rules and currency fluctuations. Nonetheless, analyst consensus projects a median target of $9, implying an upside of over 10%. In summary, the combination of deep discount valuation, solid dividend, and recent earnings beat creates a compelling case for investors willing to navigate the heightened risk profile.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price is near technical support at $7.64
- RSI suggests limited downside pressure
- Bearish MACD indicates caution
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Undervalued relative to peers (PE 9.5 vs 16.8)
- Attractive dividend yield with strong cash base
- Earnings momentum with 10% YoY net income growth
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Sustainable cash generation and dividend policy
- Exposure to Brazil’s banking sector adds macro risk
- Valuation appears stable with limited upside beyond $9
Key Metrics & Analysis
Financial Health
Revenue Growth-2.10%
Profit Margin33.28%
P/E Ratio9.5
ROE21.82%
ROA1.57%
P/B Ratio2.1
Op. Cash Flow$21.2B
Industry P/E16.8
Technical Analysis
TrendNeutral
RSI39.3
Support$7.64
Resistance$8.94
MA 20$8.25
MA 50$8.44
MA 200$7.71
MACDBearish
VolumeStable
Fear & Greed Index91.61
Valuation
Target Price$8.74
Upside/Downside11.73%
GradeUndervalued
TypeBlend
Dividend Yield1.35%
Risk Assessment
Beta1.31
Volatility30.84%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskHigh
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.